Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.
Hepatocellular Carcinoma
DRUG: Sorafenib (Nexavar, BAY43-9006)
Efficacy (analyzed by overall survival rate) of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma., at 1 year
Adverse event collection of sorafenib under real-life practice conditions in patients with Hepatocellular Carcinoma., every 4 months on average within approx. 2 years|Overall survival, at 1 year|Time to Progression, every 4 months on average within approx. 2 years
Prospective, non-interventional, multi-center study. Patients affected by Hepatocellular Carcinoma (HCC) who are candidates for systemic therapy and in whom a decision to treat with sorafenib has been made. Aim of this non-interventional, post-marketing study is to evaluate the efficacy of sorafenib in terms of overall survival rate at 12 months in patients with HCC under daily-life treatment conditions.